Effective gene therapy with nonintegrating lentiviral vectors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis. This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction. With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NILVs encoding for in vivo expression of GFP have been reported in organs such as the brain, liver, and spinal cord via stable gene transfer for longer periods (up to months) in several studies [22,73,131,132,133,134].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [22]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [49]
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Class I integration-deficient lentiviral vectors have been reported to be inefficient for transduction of dividing cells in vitro”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“We produced paired integration-proficient and integration-deficient HIV-1 vectors using self-inactivating system”
MethodNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“In contrast, direct administration of nonintegrating vectors based on human immunodeficiency virus (HIV) or feline immunodeficiency virus (FIV) has not previously resulted in significant expression in vivo”
BackgroundA quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“We carried out qPCR titrations of total vector DNA according to a published protocol for late reverse transcriptase amplicon quantificatio”
MethodMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“We designed three different LAM-PCR reactions to scan vector regions downstream of the 5¢-dLTR (1), upstream of the 3¢-dLTR (2) and downstream of residual env sequences (a region including cPPT/CTS and internal promoter, 3) for integration junctions.”
MethodSelf-citationDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationSide effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2988 · Cited by 386
Shank, P. R., Hughes, S. H., Kung, H.-J., Majors, J. E., Quintrell, N., Guntaka, R. V., Bishop, J. M., & Varmus, H. E. (1978) · Cell · doi:10.1016/0092-8674(78)90063-6 · Cited by 383
Cited by
Items 301–400 of 459
Saida, H., Matsuzaki, Y., Takayama, K., Iizuka, A., Konno, A., Yanagi, S., & Hirai, H. (2014) · Gene Therapy · doi:10.1038/gt.2014.60 · Cited by 13
Wanisch, K., Kovac, S., & Schorge, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053269 · Cited by 13
“The unique properties of lentiviral vectors, in particular their large gene packaging capacity and their ability to transduce postmitotic cells like neurons, make them ideal tools to use for gene therapy in neurosciences, even more in conjunction with the advent of non-integrating lentiviral vectors [47,48], which hav…”
Novel vectors forin vivogene delivery to vascular tissue
White, K., Nicklin, S. A., & Baker, A. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.6.809 · Cited by 12
“In vivo studies have demonstrated sustained transgene expression in the retina of mice, rats and dogs following subretinal injection of the vector [21,22] .”
BackgroundTachikawa, K., & Briggs, S. P. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.010 · Cited by 11
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping
Jargalsaikhan, B.-E., Muto, M., & Ema, M. (2025) · Viruses · doi:10.3390/v17081036 · Cited by 14
“The D64V variant had reduced integration activity by up to 1/10,000 compared to the wild-type virus [25], unintegrated vectors maintain transient gene expression from episomal DNA up to several months, and the D64V is most common variant regarding the usage of IDLVs [20,26–28].”
Use of integrase-minus lentiviral vector for transient expression.
Farazmandfar, T., Shahreza, H. K., Haghshenas, M. R., Janbabai, G., Azadeh, H., & Samaei, N. M. (2012) · PubMed Central · Cited by 14
Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease
Douglas, M. R. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.58 · Cited by 16
Semerdjieva, S., Abdul-Razak, H. H., Salim, S. S., Yáñez‐Muñoz, R. J., Chen, P. E., Tarabykin, V. S., & Alifragis, P. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01618-12 · Cited by 12
“(35) were produced as previously described (36).”
Self-citationLosing, preserving, and restoring vision from neurodegeneration in the eye
Kerschensteiner, D. (2023) · Current Biology · doi:10.1016/j.cub.2023.08.044 · Cited by 12
“Tominimize this risk, integration-deficient LVs (IDLVs) have been developed 154,155 .”
BackgroundMethodNanotherapy for Neural Retinal Regeneration
Yu, C., Dong, L., Lv, Y., Shi, X., Zhang, R., Zhou, W., Wu, H., Li, H., Li, Y., Zhou, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202409854 · Cited by 13
Gene therapy in transplantation: Toward clinical trials
Ritter, T. (2009) · PubMed · doi:10.13025/21676 · Cited by 10
Pay, S. L., Qi, X., Willard, J. F., de Godoy, J. A. P., Sankhavaram, K., Horton, R., Mitter, S. K., Quigley, J., Chang, L., Grant, M. B., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.082 · Cited by 10
Lentiviral-mediated gene transfer – a patent review
Picanço‐Castro, V., Fontes, A. M., Russo, E. M. D. S., & Covas, D. T. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.5.525 · Cited by 13
“Several successful preclinical trials correcting genetic ocular disorders have been reported [151-154] .”
BackgroundKanungo, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.066 · Cited by 10
“Most importantly, these vectors can be integration-deficient, thus avoiding the risk of insertional mutagenesis [13,14].”
BackgroundKampik, D., Basche, M., Georgiadis, A., Luhmann, U. F. O., Larkin, F., Smith, A. J., & Ali, R. R. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-26260 · Cited by 11
Self-citationIdentification of Key Residues Determining Isomerohydrolase Activity of Human RPE65
Takahashi, Y., Moiseyev, G. P., & Ma, J.-X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558619 · Cited by 10
The potential of gene delivery for the treatment of traumatic brain injury
Dooley, J., Hughes, J. G., Needham, E., Palios, K. A., & Liston, A. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03156-x · Cited by 10
“While studies demonstrate transgene persistence up to 3 months in the rat brain and up to 9 months in other tissues, extensive research is needed to ascertain expression limits [52, 53].”
BackgroundHematopoietic stem and progenitors cells gene editing: Beyond blood disorders
Buffa, V., Vargas, J. R. A., Galy, A. H. M., Spinozzi, S., & Rocca, C. J. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.997142 · Cited by 12
“, 1998) and integrative-deficient LVs (IDLVs) (Philippe et al., 2006; Yanez-Munoz et al., 2006).”
BackgroundLu‐Nguyen, N., Broadstock, M., & Yáñez‐Muñoz, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.016 · Cited by 8
“…23–27 We have previously demonstrated that the novel integration-deficient LVs (IDLVs) are as efficient as their standard integration-proficient counter-parts (IPLVs) at transducing rodent eye and brain cells in vivo 28 but have enhanced biosafety due to their reduced risk of insertional mutagenesis.”
InfluentialSelf-citationBacteriophage PRD1 as a nanoscaffold for drug loading
Duyvesteyn, H. M. E., Santos-Pérez, I., Peccati, F., Martínez-Castillo, A., Walter, T. S., Reguera, D., Goñi, F. M., Jiménez‐Osés, G., Oksanen, H. M., Stuart, D. I., et al. (2021) · Nanoscale · doi:10.1039/d1nr04153c · Cited by 9
Negro‐Demontel, M. L., Saccardo, P., Giacomini, C., Yáñez‐Muñoz, R. J., Ferrer‐Miralles, N., Vázquez, E., Villaverde, A., & Peluffo, H. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.47 · Cited by 10
Self-citationMitra, A., & Agrawal, D. K. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.8.1185 · Cited by 9
Gene Delivery into Cells and Tissues
Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00035-5 · Cited by 10
(2007) · Wiley eBooks · doi:10.1002/9780470184585 · Cited by 8
Shaw, A., Joseph, G. L., Jasti, A. C., Sastry, L., Witting, S. R., & Cornetta, K. G. (2016) · Gene Therapy · doi:10.1038/gt.2016.69 · Cited by 11
Lentiviral Gene Transfer-Mediated Cone Vision Restoration in RPE65 Knockout Mice
Bemelmans, A., Kostic, C., Cachafeiro, M. C. B., Crippa, S. V., Wanner, D., Tekaya, M., Wenzel, A., & Arsenijévic, Y. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_9 · Cited by 9
“However it has been shown recently that lentiviral vectors can be engineered to be non-integrative, and that this type of vector is efficient for gene therapy in the knockout mouse model of RPE65 deficiency (Yanez-Munoz et al., 2006).”
BackgroundBaum, C., Schambach, A., Modlich, U., & Thrasher, A. J. (2007) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-007-0385-5 · Cited by 8
Self-citationWhite, E., Bienemann, A. S., Megraw, L., Bunnun, C., Wyatt, M. J., Taylor, H., & Gill, S. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.185 · Cited by 8
“…et al. , 2000; Consiglio et al. , 2001; Azzouz et al. , 2004; Dowd et al. , 2005; Fjord-Larsen et al. , 2005; Wong et al. , 2005; Brizard et al. , 2006; Vercammen et al. , 2006; Yanez-Munoz et al. , 2006; McCoy et al. , 2008; McIntyre et al. , 2008; Spencer et al. , 2008; Torashima et al. , 2008).”
Molecular neurosurgery: vectors and vector delivery strategies
White, E. (2012) · British Journal of Neurosurgery · doi:10.3109/02688697.2012.671972 · Cited by 8
Ma, S., Lv, M., Chen, X., Zang, G., Tang, Z., Zhang, Y., & Hu, W. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105662 · Cited by 7
Stripecke, R. (2014) · Biomedicines · doi:10.3390/biomedicines2030229 · Cited by 7
“Although lower levels of transgene expression are detected in comparison to “integrase competent” (IC)LV counterparts, IDLV have been reported to lead to efficient gene expression in vitro and in vivo, most remarkably in non-dividing cells [39,40].”
BackgroundPerinatal Gene Delivery to the CNS
Rahim, A. A., Buckley, S. M. K., Chan, J. K. Y., Peebles, D., & Waddington, S. N. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.16 · Cited by 7
Borlongan, C., Suárez-Meade, P., Carvajal, H. G., Yasuhara, T., Tajiri, N., & Date, I. (2015) · Brain Circulation · doi:10.4103/2394-8108.172884 · Cited by 8
Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency
Abdul-Razak, H. H., Rocca, C. J., Howe, S. J., Alonso-Ferrero, M. E., Wang, J., Gabriel, R., Bartholomae, C. C., Gan, V. C. H., Garin, M. I., Roberts, A. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26439-9 · Cited by 7
Self-citationA Mechanistic Approach to the Development of Gene Therapy for Chronic Pain
Kibaly, C., Loh, H. H., & Law, P. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.06.002 · Cited by 8
Weaponizing CRISPR/Cas9 for selective elimination of cells with an aberrant genome
Tavella, S., di Lillo, A., Conti, A., Iannelli, F., Mancheno-Ferris, A., Matti, V., Micco, R. D., & di Fagagna, F. D. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103840 · Cited by 7
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Ioannidis, K., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie · doi:10.1002/ange.202311590 · Cited by 6
Gene delivery into cells and tissues
Nelson, C. E., Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00030-7 · Cited by 9
Viral vectors for gene delivery to the central nervous system
Ingusci, S., Hall, B. L., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00001-0 · Cited by 8
Liu, Z., & Song, S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102911 · Cited by 6
“132,133 Compared with AdV or AAV vectors, LV vectors generally induce weaker type I IFN responses.”
Generation of a Beta-Cell Transplant Animal Model of Diabetes Using CRISPR Technology
Ekşi, Y. E., Bişgin, A., Şanlioğlu, A. D., Azizoğlu, R. O., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2022_746 · Cited by 5
Nafchi, N. A. M., Chilcott, E. M., Brown, S. J., Fuller, H. R., Bowerman, M., & Yáñez‐Muñoz, R. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00406-0 · Cited by 5
“IDLVs are non-integrative due to an engineered class I mutation in the viral integrase gene, most commonly involving an amino acid change at position D64 within the catalytic core domain [31].”
Self-citationThe role ofcis-regulatory elements in the design of gene therapy vectors for inherited blindness
Corbo, J. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.599 · Cited by 6
“Potential approaches to ameliorate these drawbacks with regard to cellular targeting of expression include the use of chromatin insulators to protect the transgene from the effects of chromosomal context [36,37] or the use of integrase-deficient lentiviruses, which do not integrate into the chromosome [38] .”
Wang, C., Jiang, C., Gao, N., Zhang, K., Liu, D., Wang, W., Cong, Z., Qin, C., Ganusov, V. V., Ferrari, G., et al. (2017) · Viruses · doi:10.3390/v9060135 · Cited by 5
Alonso-Ferrero, M. E., van Til, N. P., Bartolović, K., Mata, M. F., Wagemaker, G., MOULDING, D. A., Williams, D. A., Kinnon, C., Waddington, S. N., Milsom, M. D., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.003 · Cited by 5
“In dividing cells, this results in dilution of episomal DNA with expression of the transgene rapidly falling to undetectable levels [5].”
BackgroundSelf-citationTang, P., Bo, D., Reyes, C., Papp, D., & Potter, J. (2023) · BioTechniques · doi:10.2144/btn-2023-0013 · Cited by 5
Kesseli, S. J., Krischak, M. K., Gao, Q., Gonzalez, T. J., Zhang, M., Halpern, S. E., Kahan, R., Song, M., Huffman, N., Xu, H., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.08.050 · Cited by 5
Emeagwali, N., & Hildreth, J. E. K. (2012) · Virology Journal · doi:10.1186/1743-422x-9-277 · Cited by 6
“In infections with integrase defective lentiviral vectors in animal models, reservoirs of uDNA are relatively long lived [66,67].”
Applications of Virus Vector–Mediated Gene Therapy in China
Lin, Q., Deng-gao, W., Zhang, Z., & Liu, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.238 · Cited by 5
“20 In addition, recent modifications such as adding targeting ligands ( e.g. , single-chain antibodies) to LV vectors pseudotyped with Sindbis virus and measles envelope glycoproteins enabled selective infection of various cell types by LVs. 21 Non-integrative adenovirus vectors were first used for…”
Gene Therapy Methods and Their Applications in Neurological Disorders
Li, M., & Snider, B. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00001-6 · Cited by 9
Optimizing Delivery and Expression of Designer Nucleases for Genome Engineering
Chuah, M., & VandenDriessche, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.166 · Cited by 5
“These IDLVs can be generated using conventional LV production methods, whereby the gag-pol helper construct encodes a defective integrase harboring a D64V substitution (Ya´n˜ez-Mun˜oz et al. , 2006; Ma´trai et al. , 2010, 2011).”
Gene Therapy Strategies for Usher Syndrome Type 1B
Williams, D. S., & Lopes, V. S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0631-0_31 · Cited by 4
Gene therapy in neovascular age related macular degeneration: an update
Quesada, E., Vázquez, S. R., Campos, X., & Wu, L. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06837-2 · Cited by 5
Genetic therapies for neurological diseases
Rahim, A. A., Kurian, M. A., Zhou, H., Ferguson, R., Tabrizi, S. J., Lignani, G., Aquilina, K., & Waddington, S. N. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100093 · Cited by 5
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 8
N -Methyl-D-Aspartate Receptors
Iacobucci, G. J., & Popescu, G. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190669164.013.16 · Cited by 4
Assessment of Different Virus-Mediated Approaches for Retinal Gene Therapy of Usher 1B
Lopes, V. S., Diemer, T., & Williams, D. S. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_91 · Cited by 4
Viral Vectors for Gene Therapy
Philpott, N. J. (2007) · Wiley eBooks · doi:10.1002/9780470015902.a0020707 · Cited by 4
Therapeutic Gene Editing in Inherited Retinal Disorders
Ling, J., Jenny, L. A., Zhou, A., & Tsang, S. H. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041292 · Cited by 5
Prospects of gene and cell therapy for managing cardiac complications in Friedreich ataxia
Isaacs, C. J., Shinnick, J. E., Schadt, K. A., Lynch, D. R., & Lin, K. Y. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1083854 · Cited by 3
“Alternately, newer non-integrating lentiviral vectors featuring mutations in the integrase protein can transduce host cells and produce circular vector episomes that are translated into the desired protein without integration into the host genome [63,64].”
BackgroundRetrovirus Integration: Some Assembly Required?
Ali, I., Conrad, R. J., & Ott, M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.11.003 · Cited by 4
“These retroviruses diminish risk of cancerous cell transformation but generally exhibit lower levels of gene expression (Yáñez-Muñoz et al., 2006).”
BackgroundGene therapy in hereditary retinal dystrophy
Chien, J.-Y., & Huang, S. (2022) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_78_22 · Cited by 4
“The virus infects host cells and inserts DNA fragments into the host genome or by nonintegrating stable transduction [13], replicating the genetic materials and producing protein.”
BackgroundPTEN Mediates the Silencing of Unintegrated HIV-1 DNA
Phan, A. T., & Zhu, Y. (2024) · Viruses · doi:10.3390/v16020291 · Cited by 3
Recent developments in gene therapy research in India
Selot, R., & Ghosh, A. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00423-0 · Cited by 7
“To overcome this limitation, integration-deficient lentiviruses have been successfully generated and tested in animal models (Yanez-Munoz et al. 2006; Dong and Kantor 2021).”
Gene Therapy Approaches to Ataxias
Lim, F., & Díaz‐Nido, J. (2009) · Current Gene Therapy · doi:10.2174/156652309787354649 · Cited by 3
“Lentivectors packaged using an integrase mutant have been shown to drive persistent transgene expression in neurons [90] but as discussed above, their cargo size is limited.”
BackgroundSelectable Markers for Gene Therapy
Gottesman, M. M., Licht, T., Kimchi‐Sarfaty, C., Zhou, Y., Lee, C. G. L., Shoshani, T., Hafkemeyer, P., Hrycyna, C. A., & Pastan, I. (2000) · CRC Press eBooks · doi:10.1201/9781420002126-28 · Cited by 3
Bryson, P. D., & Wang, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394295-1.00024-x · Cited by 11
Viral Vectors for Gene Delivery
Dismuke, D. J., Gray, S. J., Hirsch, M. L., Samulski, R. J., & Muzyczka, N. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732239-00338 · Cited by 3
Replicating Minicircles: Overcoming the Limitations of Transient and Stable Expression Systems
Nehlsen, K., Broll, S., Kandimalla, R., Heinz, N., Heine, M. A., Binius, S., Schambach, A., & Bode, J. (2013) · Wiley eBooks · doi:10.1002/9783527670420.ch8 · Cited by 3
In vivo engineering of immunosuppressive T cells to treat ocular autoimmune diseases
Wang, D., Ling, J., Liang, J.-J., Li, J. W., Hu, Q., Yang, L., Jin, J., Bai, X., Zheng, Y., Lin, B., et al. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111041 · Cited by 2
Takayama, K., & Torashima, T. (2009) · Journal of NeuroVirology · doi:10.3109/13550280903214091 · Cited by 2
Hematopoietic Stem Cell-Based Therapy for HIV Disease: A Role for Regulatory T Cells
Schaefer, J. B. P. K. R. K. K. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000300 · Cited by 2
“An alternative gene transfer approach is to utilize viral vectors that have been modified such that they are unable to integrate into the host genome [29].”
BackgroundLu‐Nguyen, N., Broadstock, M., & Yáñez‐Muñoz, R. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3753-0_13 · Cited by 2
Self-citationNakai, H. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_23 · Cited by 3
Transgene Delivery to Endothelial Cultures Derived from Porcine Carotid Artery Ex Vivo
Andoh, J., Sawyer, B., Szewczyk, K. A., Nortley, M., Rossetti, T., Loftus, I. M., Yáñez‐Muñoz, R. J., & Hainsworth, A. H. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0261-6 · Cited by 2
Self-citationTian, P., Peng, C., & Zhang, L. (2015) · RSC Advances · doi:10.1039/c5ra03740a · Cited by 2
Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo
Ellis, S., Fong-Wong, L., Iqball, S., Thoree, V., Mitrophanous, K. A., & Binley, K. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.53 · Cited by 2
Cellular Engineering and Disease Modeling with Gene-Editing Nucleases
Osborn, M. J., & Tolar, J. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_12 · Cited by 3
Vectors in gene therapy: Benefit for glioblastoma patients
Carver, K., Negrete, D., Waterman, M., & Daddacha, W. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822527-1.00011-3 · Cited by 3
Platelet-Directed Gene Therapy
Ohmori, T., & Sakata, Y. (2007) · Transfusion Medicine and Hemotherapy · doi:10.1159/000109840 · Cited by 2
Development of viral & non-viral episomal vectors for gene therapy applications
Kymäläinen, H. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 3
HIV Preintegration Transcription and Host Antagonism
Wu, Y. (2023) · Current HIV Research · doi:10.2174/1570162x21666230621122637 · Cited by 2
“Even so, given the large population of transcribing uD-NA, an unintegrated lentiviral vector can be as effective as an integrated vector for expressing genes in non-dividing cells with the use of proper internal promoters [96-98].”
BackgroundMethodGoodspeed, K., Armstrong, D. M., Boitnott, A., Dolce, A. M., Ling, Q., & Gray, S. J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0076 · Cited by 1
Regulation of expression of unintegrated and integrated HIV-1 DNA: keeping the wolves at bay
Goff, S. P. (2024) · Frontiers in Virology · doi:10.3389/fviro.2024.1481451 · Cited by 2
Clinical Application of Drug Delivery Systems for Treating AMD
Kuno, N., & Fujii, S. (2012) · InTech eBooks · doi:10.5772/31861 · Cited by 1
“Highly deleted (Molina et al., 2004), selfinactivating (Berkowitz et al., 2001) and non-integrating (Yanez-Munoz et al., 2006) lentiviral vectors have been developed as safer vectors.”
BackgroundKane, N. M., Denning, C. N., & Baker, A. H. (2010) · Springer eBooks · doi:10.1007/978-3-642-11865-4_7 · Cited by 1
A Southern Blot Protocol to Detect Chimeric Nuclease-Mediated Gene Repair
Rocca, C. J., Abdul-Razak, H. H., Holmes, M. C., Gregory, P. D., & Yáñez‐Muñoz, R. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-761-7_21 · Cited by 1
“Delivery of the corrective cassette and the genes encoding the ZFN monomers may be achieved by several methods, in our case integration-deficient lentiviral vectors (IDLVs) [21, 22].”
MethodSelf-citationGene Therapy for Spinal Cord Injury
Goganau, I., & Blesch, A. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_8 · Cited by 1
“Non-integrating/integration-defi cient LV might decrease this risk while maintaining rather stable expression in nondividing cells [ 60 ].”
BackgroundMichelini, Z., Negri, D. R. M., Biava, M., Baroncelli, S., Spada, M., Leone, P., Bona, R., Blasi, M., Négre, D., Klotman, M. E., et al. (2014) · Viral Immunology · doi:10.1089/vim.2014.0062 · Cited by 1
“Studies performed in vivo confirmed that the IDLV stably transduces nondividing cells, such as brain cells (35), ocular cells (49), and muscle cells (2), representing an encouraging alternative to their IN-competent counterpart, reducing potential events of insertional mutagenesis (45).”
Development of Retroviral and Lentiviral Vectors
Escors, D., Kochan, G. T., Stephenson, H. N., & Breckpot, K. (2012) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-3-0348-0402-8_2 · Cited by 1
Multifunctional Nanoscale Delivery Systems for Nucleic Acids
Conroy, R., & Seto, B. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4372-7_18 · Cited by 1
“Such expression can occur for a relatively long duration in nondividing cells, such as retina cells [28, 29], or transiently in dividing cells.”
BackgroundTowards β-globin gene-targeting with integrase-defective lentiviral vectors
Inanlou, D. N., Yakhchali, B., Khanahmad, H., Gardaneh, M., Movassagh, H., Cohan, R. A., Ardestani, M. S., Mahdian, R., & Zeinali, S. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0351-4 · Cited by 1
“Recent studies have shown that class I defective mutations (including mutations in the catalytic domain) can strongly inhibit random integration of the LV vectors (Yáñez-Muñoz et al. 2006).”
BackgroundResultDeliverable transgenics & gene therapy possibilities for the testes
Darbey, A. L., & Smith, L. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.023 · Cited by 4
NOSE TO BRAIN DELIVERY: ROLE OF VIRAL AND NON-VIRAL VECTORS FOR NEUROLOGICAL DISORDER
Musale, S., & Giram, P. S. (2021) · INDIAN DRUGS · doi:10.53879/id.58.05.12489 · Cited by 2
Delivery Methods for CRISPR/Cas Reagents
Ashraf, S., Munawar, N., Zahoor, M. K., Jamil, A., Hammad, M., Ghaffar, A., & Ahmad, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-6305-5_4 · Cited by 2
Perspectives for the future developments of gene therapy for autoimmune and inflammatory therapy
Chernajovsky, Y., & Robbins, P. D. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_15 · Cited by 1
“Following transduction of target cells, the lentiviral proviral DNA is maintained in circular, vector episomes [67, 68 ].”
BackgroundPrecision Genome Surgery with Meganucleases: A Promising Biopharmaceutical for Gene Therapy
Pingoud, A. M., Silva, G. H., & Wende, W. (2013) · Wiley eBooks · doi:10.1002/9783527669417.ch9 · Cited by 1
Gene Therapy in Organ Transplantation
Ritter, T., & Griffin, M. D. (2012) · Wiley eBooks · doi:10.1002/9781119967309.ch9 · Cited by 1
Mammeri, H. (2006) · HAL · Cited by 1
Delivery Strategies for RNAi to the Nervous System
Foust, K. D., & Kaspar, B. K. (2011) · Neuromethods · doi:10.1007/978-1-61779-114-7_4 · Cited by 1
Metadata
- Authors
- Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., Duran, Y., Bartholomae, C., von Kalle, C., Heckenlively, J. R., Kinnon, C., Ali, R. R., & Thrasher, A. J.
- Affiliations
- University College London (GB)
- University of Freiburg (DE)
- Great Ormond Street Hospital (GB)
- Corresponding author
- Ali, Robin R
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-02-19
- Volume
- 12
- Issue
- 3
- Pages
- 348-353
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2167845957
- Cited by
- 460
- References
- 30
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 8 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 31 · 2013: 27 · 2012: 35
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- University College London
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, retroviral vectors, stable transgene expression, ocular gene therapy, retinal degeneration, postmitotic tissues
- MeSH terms
- Retinoid Isomerohydrolase, Animals, Brain, Carrier Proteins, Electroretinography, Eye Proteins, Female, Genetic Vectors, HeLa Cells, Humans, Pigment Epithelium of Eye, Retina, Tumor Cells, Cultured, Genetic Therapy, Lentivirus, Virus Integration, cis-trans-Isomerases, Green Fluorescent Proteins, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.